Le Lézard
Classified in: Health, Science and technology
Subject: AWD

Dr. Paul Janssen Award for Biomedical Research Issues 2018 Call for Nominations to Celebrate Champions of Science



NEW BRUNSWICK, N.J., Jan. 3, 2018 /PRNewswire/ -- Nominations are now being accepted for the 2018 Dr. Paul Janssen Award for Biomedical Research. This prestigious award celebrates today's most dedicated researchers and champions of science whose basic or clinical discoveries have made, or have the potential to make, significant contributions toward improving human health. Nominations will be accepted until February 28, 2018 at www.pauljanssenaward.com for consideration by an independent selection committee of world-renowned scientists. A $200,000 cash prize will be awarded to the scientist or group of scientists receiving the Award.

The Dr. Paul Janssen Award for Biomedical Research honors Dr. Paul Janssen (1926-2003), one of the most productive pharmaceutical scientists of the 20th century, who was responsible for breakthrough treatments in key disease areas including pain management, psychiatry, infectious disease and gastroenterology. Janssen founded Janssen Pharmaceutica, N.V., now part of the Johnson & Johnson Family of Companies (NYSE: JNJ).

"Behind every discovery that holds the promise for saving and improving lives are the scientists who pursue a vision and work tirelessly for many years to make it all possible," said Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson. "We are proud to honor the legacy of Dr. Paul by recognizing the outstanding researchers and champions of science who make a lasting impact on our world."

In 2017, the Dr. Paul Janssen Award recognized trailblazing scientist Douglas Wallace, Ph.D., of the Children's Hospital of Philadelphia, for pioneering the field of mitochondrial genetics and its application to the study of disease, aging, and patterns of human migration.

"Scientific research is crucial to advancing our understanding of the mechanisms underlying human health and disease," said David Julius, Ph.D., Professor and Chair of the Department of Physiology at the University of California, San Francisco, and Chair of the 2018 Dr. Paul Janssen Award selection committee. "The selection committee encourages nominations of scientists from academia, industry, government and scientific institutions around the world who champion science through the work they do everyday and exemplify the leadership and passion of Dr. Paul."

Previous Award winners include:

To learn more about past Dr. Paul Janssen Award winners, visit www.pauljanssenaward.com.

The 2018 Dr. Paul Janssen Award winner will be announced in spring 2018.

About The Dr. Paul Janssen Award for Biomedical Research
Established by Johnson & Johnson, The Dr. Paul Janssen Award salutes champions of science and the most passionate and creative scientists in basic or clinical research whose scientific achievements have made, or have strong potential to make, a measurable impact on human health. The Award is named after the scientist who founded Janssen Pharmaceutica, N.V. in 1953. Known to his colleagues as "Dr. Paul," Janssen helped save millions of lives through his contribution to the discovery and development of more than 80 medicines, four of which remain on the World Health Organization's list of essential medicines. In 1961, Janssen Pharmaceutica, N.V. joined the Johnson & Johnson Family of Companies. Janssen's legacy continues to inspire Johnson & Johnson and its commitment to finding innovative cures for unmet medical needs. Visit www.pauljanssenaward.com for more information.

About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 132,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

 (PRNewsfoto/Johnson & Johnson)

 

SOURCE Johnson & Johnson


These press releases may also interest you

at 09:30
Global Human Platelet Lysate Market to be Driven by Increased Funding and Rise in Research Centers Across the Globe According to a new study published by Persistence Market Research (PMR), the global human platelet lysate market is estimated to be...

at 09:30
The Michael J. Fox Foundation for Parkinson's Research (MJFF) announces "Parkour 4 Parkinson's," a first-time Team Fox event organized by "American Ninja Warrior" Host and Foundation Board member Akbar Gbajabiamila. Combining the camaraderie and...

at 09:28
Theragnostics Ltd is a global company dedicated to developing radiopharmaceuticals for cancer patients. Today they announce the enrolment of their first patient in their Phase II open label clinical study in London, UK. The study will assess the...

at 09:25
Livongo Health, the leading consumer digital health company empowering all people with chronic conditions to live better and healthier lives, today announced that use of Livongo for Diabetes across a broad, real-world population of people with type 2...

at 09:17
Centauri Health Solutions, Inc.®, the Scottsdale-based provider of technology-enabled revenue optimization and quality of care services to health plans, health care providers, hospitals, and health systems, has acquired NHI Billing Services (NHI), a...

at 09:15
Aethlon Medical, Inc. , a therapeutic technology company focused on unmet needs in global health and biodefense, today announced the appointment of Guy Cipriani to its Board of Directors. Mr. Cipriani qualifies as an independent director under the...




News published on 3 january 2018 at 15:00 and distributed by: